Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp (TWST) reported an insider transaction by its President and COO on a Form 4. On 11/21/2025, the officer sold 1,776 shares of common stock at a price of $26.5035 per share. After this transaction, the officer beneficially owned 332,883 shares directly.
The company explains that these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units. The sale was mandated under the company’s equity incentive plans as a "sell to cover" transaction and is described as not a discretionary trade by the reporting person.
Twist Bioscience Corp (TWST) reported a small insider transaction by its Senior Vice President of Human Resources, Paula Green. On 11/21/2025, Green sold 598 shares of common stock at a price of $26.5035 per share. After this transaction, she beneficially owned 167,789 shares directly.
The company explains that the sale was made to cover tax withholding obligations triggered by the vesting of Restricted Stock Units. These transactions are described as mandated under Twist Bioscience’s equity incentive plans through a “sell to cover” election, meaning they are not discretionary trades initiated by the executive for portfolio reasons.
Twist Bioscience Corporation's Chief Financial Officer reported an automatic sale of company stock to cover taxes. On 11/21/2025, the reporting person sold 887 shares of common stock at a price of $26.5035 per share. The filing explains that these shares were sold under a mandatory "sell to cover" arrangement tied to the vesting of Restricted Stock Units, meaning the transaction was not a discretionary trade. After this tax-related sale, the officer beneficially owned 142,769 shares of Twist Bioscience common stock in direct ownership.
Twist Bioscience Corp (TWST) reported an insider transaction by its Chief Executive Officer and director, Emily M. Leproust. On 11/21/2025, she disposed of 2,663 shares of common stock at a price of $26.5035 per share in a sale coded "S." This sale was made to cover tax withholding obligations triggered by the vesting of restricted stock units, and is described as a mandatory "sell to cover" under the company’s equity incentive plans rather than a discretionary trade.
Following this transaction, Leproust beneficially owned 878,173 shares of common stock, held directly. She also holds several employee stock options with various exercise prices and vesting schedules, including performance stock options granted on September 1, 2020 that vested and became exercisable on December 19, 2022 after meeting specified performance criteria.
Twist Bioscience Corp (TWST) reported insider share sales by its Chief Accounting Officer. The reporting person sold 229 shares of common stock on 11/21/2025 at a price of $26.5035 per share and 822 shares on 11/24/2025 at a price of $28.7095 per share. After these transactions, the officer beneficially owned 66,143 shares of Twist Bioscience common stock in direct ownership.
According to the explanation, the 229 and 822 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, and the sales did not represent discretionary trades by the officer.
Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of $0 per share, increasing her directly held beneficial ownership to 880,836 common shares.
The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to continued service. The filing also lists multiple outstanding employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85, covering hundreds of thousands of shares with expiration dates between 2027 and 2030. Some older options at $5.95 now show zero remaining shares.
Twist Bioscience Corp (TWST) reported a routine insider equity grant to its President and COO, Patrick John Finn. On 11/18/2025, he received 68,740 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share. Following this grant, he beneficially owned 334,659 shares of Twist Bioscience common stock in total.
The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, subject to his continued service. This structure ties a portion of the executive’s compensation to the company’s long-term performance and his ongoing role.
Twist Bioscience Corp (TWST) reported that its Chief Financial Officer received a grant of 32,648 restricted stock units (RSUs) of common stock on 11/18/2025. The RSUs were recorded at a price of $0 because they are equity awards rather than open‑market purchases.
Following this grant, the CFO beneficially owns 143,656 shares of Twist Bioscience common stock in total. The RSU award vests over four years: 1/16 of the total RSUs vest on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, as long as the executive remains in continuous service through each vesting date.
Twist Bioscience Corp (TWST) officer Dennis Cho reported a grant of 25,465 restricted stock units (RSUs) of common stock at a price of $0 per share. After this equity award, he beneficially owns 146,159 shares of Twist Bioscience common stock in total.
The RSU award vests over four years, with 1/16 of the RSUs vesting on each quarterly anniversary of November 20, 2025, for a total vesting period of 48 months, subject to his continuous service with the company. Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and this Form 4 reflects routine insider equity compensation.
Twist Bioscience Corp. (TWST) reported an equity award to a senior executive. Officer Paula Green, the company’s SVP of Human Resources, received 26,200 shares of common stock in the form of a restricted stock unit (RSU) grant on 11/18/2025 at a stated price of $0, reflecting a compensatory award rather than an open‑market purchase.
The RSUs vest over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to her continued service through each vesting date. Following this grant, Paula Green beneficially owns 168,387 shares of Twist Bioscience common stock, held directly.